VertexPharma wants to transform the treatment of pain. An upcoming sciatica clinical trial readout will be pivotal.

Vertex (VERX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

AI Studio is all about helping companies create and deploy Box AI “agents” that are customized to perform specific business ...

DataRobot also announced large and unstructured data preparation handling automation tools to help businesses assess data ...

Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

The company purchased additional entitlements for the areas of the business that we did not previously serve across a very ...

Federal Territory of Kuala Lumpur, Malaysia - November 5, 2024 — SurgeGraph, one of the leading AI writing tools, today ...

Thoughtworks' 2024 Technology Radar highlights rapid AI growth in software engineering, urging developers to adopt best ...

VRTX to report Q3 earnings, expected EPS $4.14 and $2.72B in revenue. Cramer calls it a buy, analysts see 22% upside. Stock ...